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Abstract
Background: Myotonic dystrophy type 1 (Steinert’s disease or DM1), the most common form of autosomal
dominant muscular dystrophy in adults, is a multisystem disorder, affecting skeletal muscle as well as eyes, heart,
gastrointestinal tract, endocrine system, and central nervous system, finally responsible of increasing disabilities and
secondary social consequences. To date, DM1-related brain involvement represents a challenging field of research.
It is well known that DM1 patients frequently present neuropsychological disturbances and psychiatric
comorbidities among which reduced awareness of disease burden and its progression, also defined as anosognosia,
is common in clinical practice, this leading to secondary misattribution of symptoms, delay in timely diagnostic
procedures and low compliance to treatment.
Methods: Here we present an observational cross sectional study in which disease-related cognitive dysfunctions
and quality of life were assessed by a protocol finally designed to estimate the prevalence of disease awareness in
a sample of 65 adult-onset DM1 patients.
Results: Our analysis showed that in DM1 patients several cognitive functions, including executive and mnesic
domains with visuo-spatial involvement, were affected. The assessment of anosognosia revealed that a high
percentage (51.6 %) of DM1 subjects was disease unaware. The reduced illness awareness occurs across different
physical and life domains, and it appears more prominent in Activities and Independence domains investigated by
the Individualized Neuromuscular Quality Of Life (INQoL) questionnaire. Moreover, the unawareness resulted
significantly related (at p <0.05 and p < 0.01) to the performance failure in cognitive tests, specifically in the
domains of visuo-spatial memory, cognitive flexibility and conceptualization.
Conclusions: The obtained data confirm, by a systematic analysis, what’s the common clinical perceiving of disease
unawareness in Steinert’s disease, this related to the already known cognitive-behavioural impairment of frontal
type in affected patients. We believe that a deep knowledge of this aspect will be useful for medical practice in the
management of patients with DM1, also for guidance in occupational and social interventions, definition of
outcome measures and in preparation of trial readiness.
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Background
Myotonic dystrophy type 1 (DM1, Steinert’s disease) is
the most common form of muscular dystrophy in adults,
with a prevalence of about 1 in 8,000 people worldwide.
It is an autosomal dominant disorder due to an unstable
cytosine-thymine-guanine (CTG) triplet repeat expan-
sions within the noncoding 3’ untranslated region of the
myotonic dystrophy protein kinase (DMPK) gene on
chromosome 19q35 [1–3]. The mutation causes mis-
splicing of mRNA species which can affect many cellular
processes in different organs and tissues. There is not al-
ways a clear correlation between phenotype and genetic
repeat size [4]. In general, longer CTG repeat expansions
are associated with an earlier age of onset and more dis-
abling disease. Based on age at onset and clinical expres-
sion, DM1 can be classified into three clinical forms,
congenital, childhood and classic or late-onset [5, 6].
Children with congenital DM1 present hypotonia and
severe generalized weakness at birth, often with respira-
tory insufficiency and early death; intellectual disability
is also frequent. Childhood and classic DM1 forms, ran-
ging from mild to more severe phenotype, can be con-
sidered as a multisystem disorder, that affects skeletal
muscle as well as eyes, heart, gastrointestinal tract,
endocrine system, and central nervous system (CNS), fi-
nally responsible of an increasing disability and second-
ary social consequences.
To date, DM1-related CNS involvement represents a
challenging field of research. Several CNS imaging stud-
ies have documented brain abnormalities in DM1 pa-
tients. Routine brain magnetic resonance imaging often
shows non specific pathological findings such as white
matter hyperintense lesions, ventricular enlargement and
brain atrophy in temporal and frontal lobes, brainstem
nuclei, thalamus and basal ganglia [7–11]. Single photon
emission computed tomography perfusion imaging or
18 F-deoxy-glucose positron emission tomography dem-
onstrated the presence of hypoperfusion/hypometabo-
lism in frontal and temporal lobes [9, 12, 13]. Moreover,
several neuropathological evidences confirmed a diffuse
cell loss in specific areas of the brain, neuronal eosino-
philic inclusion bodies in the thalamic nuclei, substantia
nigra and caudate nucleus, neurofibrillary tangles of the
type seen in Alzheimer’s disease and other neurodegen-
erative disorders in the hippocampus, entorhinal cortex
and temporal areas [14].
Notably, in the last 20 years, several studies have well
documented that DM1 is frequently associated with dif-
ferent neuropsychological deficits and psychiatric
comorbidities.
Cognitive functioning
Intelligence assessment documented an intelligence quo-
tient (IQ) below normal for age in the DM1 population
as compared to healthy subjects, with no clear evidence
of a progressive intellectual decline [14, 15]. Several
studies have demonstrated that DM1 patients show se-
lective impairments in cognitive functioning, particularly
in attentive, visuo-spatial, and executive domains [16,
17]. In 2004 Modoni and coworkers [18] strengthened
this issue by studying a large cohort of patients stratified
by CTG size: the authors demonstrated that visuo-
spatial deficits are recurrent features in the neuro-
psychological profile of adult patients with DM1, regard-
less the size of CTG expansions. More recently, the
concept of a “DM1-related-dysexecutive-syndrome” has
been proposed to define the heterogeneous neuro-
psychological involvement in DM1 [14]. Nevertheless, it
is still unclear whether in these patients there is a pro-
gression of cognitive decline over time [19], and whether
the brain abnormalities evolve in dementia syndrome.
Language function is generally preserved in patients with
adult DM1 [12, 16], although speech abnormalities (dys-
artria) due to facial weakness or tongue/jaw muscle
myotonia can result in difficulties in oral communication
and social inclusion, with concern for patients and their
families.
Neuropsychiatric involvement
Beside cognitive impairments, in DM1 patients’
neuropsychiatric comorbidities are frequently reported
with variable pathologic behavioral patterns. A high
prevalence of dysfunctional personality has been de-
scribed [16, 20], mainly in dependent, avoidant,
obsessive-compulsive and schizotypal dimensions. In
2006 Winblad and coworkers [21] demonstrated that
facial emotion recognition is also affected in DM1 pa-
tients, with some common features resembling schizo-
phrenia, suggesting a possible similar pathophysiology.
The occurrence of mood disorders is also reported
[17, 22]. Affective and depression-like symptoms are
frequently observed in DM1 subjects, whereas only
few patients fully match the criteria for a depressive
disorder [16, 23]. Lack of interest (apathetic behav-
iour), a decreased emotional participation and an in-
creased irritability are common features, also defined
as “an emotional imbalance” [24, 25].
Disease awareness
In clinical practice, it is commonly noted that subjects
affected by DM1 often show a reduced awareness of dis-
ease burden and its progression, also defined as anosog-
nosia or lack of insight, this leading to secondary
misattribution of symptoms, delay in timely diagnostic
procedures and low compliance to treatment [14, 26].
The unawareness of disease can be observed in individ-
uals with brain lesions or neurodegenerative disorders,
such as Alzheimer's disease, in which it can be a direct
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consequence to the underlying pathological process itself
[27]. Psychopathological mechanisms have been also hy-
pothesized to be involved in the genesis of anosognosia.
In our knowledge, to date, a systematic characterization
of the occurrence of anosognosia and its correlation with
the neuropsychological dysfunctions in individuals with
DM1 is not available.
Here we present an observational cross sectional study
in which disease-related cognitive dysfunctions and qual-
ity of life were assessed by a protocol finally designed to
estimate the prevalence of disease awareness in a sample
of adult-onset DM1 patients.
Methods
Study design
From December 2012 to December 2014, we consecu-
tively screened 81 patients with clinical and genetic
diagnosis of adult form of DM1, according the Inter-
national Consortium for myotonic dystrophies guide-
lines [28], referred to Neurological Clinic of
University of Pisa and S. Camillo IRCCS Institute of
Venice. Patients with mental retardation (IQ < 70), se-
vere visual impairment, psychiatric illness and a his-
tory of substances abuse were excluded. The final
sample included 65 subjects (63 % males, 37 % fe-
males; mean age: 46.1 ± 12.3 years; age range: 18–70
years) (Table 1). None of the patients presented
motor or coordination disability sufficient to account
for possible delay in any of the neuropsychological
tests administered.
A group of 26 sex-and-age-matched healthy control sub-
jects was also recruited. The study was authorized by the
Pisa University Medical Ethics Committee (CEAVNO,
North-West Tuscany Ethical Committee) and it was
conducted according to the principles expressed in
the Declaration of Helsinki; participants were asked
to fill in a written informed consent form, in which
they state that they have been adequately informed
about the study procedures.
The experimental protocol was displayed into three
examination sessions: a) comprehensive clinical evalu-
ation, b) neuropsychological examination and c) assess-
ment of quality of life and disease unawareness.
a) The neurological examination included clinical
history collection and evaluation of muscle
involvement, scored by Muscular Impairment Rating
Scale (MIRS) and Medical Research Council scale
(MRC) [29]. All patients were sub-grouped on the
basis of CTG expansion size (Table 1). A complete
assessment of extra-muscular clinical features was
also performed, including evaluation of cardiac, re-
spiratory, gastro-intestinal, ocular and endocrino-
logical involvement.
b) Neuropsychological evaluation was performed in
two phases; intellectual functioning was evaluated
using Brief Intelligence Test (TIB), an Italian test for
premorbid IQ estimation, in order to recruit only
patients with IQ within the normal ranges. The first
phase aimed to achieve behavioural characterization
of DM1 patients. A psychological consultation was
performed including psychometric assessment of
depressive and anxiety symptoms, by Beck
Depression Inventory-II (BDI-II) [30], State-Trait
Anxiety Inventory-2 (STAI-Y2), [31], and of apath-
etic behaviour by Apathy Evaluation Scale (AES)
(Table 2), [32]. In the second session patients under-
went complete neuropsychological cognitive evalu-
ation battery composed by: Immediate and Delayed
Recall (IR, DR) of Rey Auditory Verbal Learning
Test (RAVLT), Immediate and Delayed Recall (IR,
DR) of Rey Osterrieth Complex Figure (ROCF), digit
span and Corsi’s block test (CBT) to assess immedi-
ate memory, Trail Making Tests (TMT A and B) to
assess selective attention and cognitive flexibility,
Stroop Test to assess automatic response inhibition,
phonemic verbal fluency test (FAS), Frontal Assess-
ment Battery (FAB) and Modified Wisconsin Card





Age 46.1 ± 12.3 yrs
Age range:
18–70 yrs
Sex F = 37 % (24)
M = 63 % (41)
Age at onset 31.5 ± 14.7 yrs
[CTG]n E1 37.7 % (25)
[CTG]n E2 58.5 % (38)
[CTG]n E3 3.8 % (2)
Transmission 78 % paternal
22 % maternal
Educational level Mean 11.6 ± 3.5 yrs
Time from disease onset Mean 10.2 ± 7.4 yrs
Severity of muscular involvement (MIRS) Mean = 2.85 ± 1
MIRS = 1 7.3 %
MIRS = 2 36.4 %
MIRS = 3 27.3 %
MIRS = 4 21.8 %
MIRS = 5 7.3 %
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Sorting Test (WCST), to assess frontal and executive
functions, Rey-Osterrieth Complex Figure to assess
spatial organization and visuo-constructional skills
(ROCF), and Raven’s progressive matrices (PM47) to
assess culture-free abstract reasoning [33, 34]. Pa-
tients’ raw scores were corrected according to Italian
normative values (Table 3).
Neuropsychological assessment was performed by an
experienced examiner in a quiet and comfortable
medical office. Each examination session lasted
about 90 min.
c) In order to investigate the disease subjective
experience, we decided to use the Individualized
Neuromuscular Quality of Life Questionnaire
(INQoL) [35], a structured interview consisting of
10 items that capture patient’s physical and
psychosocial limitations related to the muscle
disease. Motor impairment is evaluated by items (1–
4) referring to the impact of common muscle
disease symptoms like weakness, pain and fatigue.
Psychosocial limitations in daily activities are
investigated by questions (5–9) referring to the
impact of muscular symptoms on Life Domains,
such as activities, independence, relationships,
emotions and body image. Participants respond to
the various issues using a seven-point Likert scale,
thus allowing to obtain a patient-weighted score for
each section [36]. Section scores and a total score
are then calculated in term of percentage: a higher
percentage is indicative of a greater negative impact
on quality of life.
Assessment of disease unawareness
Disease unawareness can be defined as an altered ability
to recognize the presence or appreciate the severity of
deficits in sensory, perceptual, motor, affective, or cogni-
tive functioning and it has been operationally defined in
a variety of ways. However, tools currently available for
evaluation of disease-awareness are still under debate,
since this dysfunction is closely related to the kind of ill-
ness to be investigated. In clinical practice, structured
interviews, or questionnaires, addressed to patients and
measures of discrepancy between main caregiver and
self-reported clinical symptoms are commonly used [37].
Table 2 Psychological characterization of DM1 patients by
clinical scale administration (Beck Depression Inventory, BDI-II;
State Trate Anxiety Inventory, STAI-Y2; Apathy Evaluation Scale,
AES) BDI-II: total score ranges 0–63, normal ratings ranking
below 9 for men and o13 for women STAI-Y2: total score ranges
20–80, threshold value = 40 AES: total score ranges 0–54, cut-off
threshold = 18
Mean (SD)
BDI-II (depressive symptoms) 10.6 (8.4)
STAI-Y2 (anxiety symptoms) 39.1 (10.0)
AES (apathetic behaviour) 18,2 (9.5)
Table 3 Neuropsychological functioning. Test scores are expressed as mean, (SD). Percentages of impairment (% impaired) are
related to available cut-off scores of normality (≥95 % of the tolerance limit of the normal population distribution); statistically signifi-
cant differences between patients and healthy controls are shown in bold
DM1 patients (n = 65) Controls (n = 26)
mean corrected scores % impaired mean corrected scores p-value
RAVLT IR 42 (7.2) 5.8 46.8 (8.4) .013
RAVLT DR 9.1 (1.8) 1.9 9.8 (2.5) .370
Rey Osterrieth Figure (ROCF) Copy 27.5 (6.5) 46.9 32 (6.5) .007
Rey Osterrieth Figure (ROCF) IR 13.8 (6.0) 32.7 19.8 (6.6) < .001
Rey Osterrieth Figure (ROCF) DR 13.2 (6.7) 36.7 19.7 (6.4) < .001
Digit Span 5.1 (1.1) 24 6.2 (1.2) .002
Corsi’s Block Test (CBT) 4 (0.8) 43.1 5 (0.8) < .001
Trail Making Test A (TMT A) 55.5 (34.9) 21.3 41 (14.3) .003
Trail making Test B (TMT B) 130.5 (60) 17.4 108.3 (47.2) .072
FAS (phonemic fluency) 28.4 (9.8) 25.5 44.7 (9.0) < .001
FAB 15 (1.4) 25 16.3 (0.6) < .001
STROOP Time Interference 32.8 (24.8) 32.7 18.9 (6.4) < .001
STROOP Error Interference 3.2 (4.4) 36.7 1 (0.9) .001
PM47 30.8 (36.4) 18.9 30.6 (2.3) < .001
WCST Categories (Cat) 3.8 (1.9) 43.4 5.6 (0.8) < .001
WCST Perseverative Errors (pe) 5.5 (4.4) 47.2 1.9 (1.2) < .001
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To be eligible for the interview, caregivers have not to
suffer from DM1 or from other illnesses affecting cogni-
tive function.
In this study, patients responses to question asked
about their functional capacities were studied and com-
pared, and the following experimental protocol was spe-
cifically designed to evaluate the occurrence of
anosognosia in each DM1 patient:
1) comparison between the severity of motor impairment
scored by MIRS (administered by a trained clinician),
and symptoms complained by patients and assessed by
INQoL Weakness Domain (administered by a
psychologist): we evaluated the statistical agreement
between these two different assays.
2) administration of INQoL questions 5–9, regarding
the Life Domains, such as Activities, Independence,
Social Relationships, Emotions, both to patient and,
separately, to the main caregiver, as already
performed to test disease awareness in neurological
disorders [37] the discrepancy score (D) was
calculated as the difference between patients’ and
caregiver’s scores (eg. D (item 1) = caregiver score –
patient score). We considered the difference of 2
points or more in at least 2 items as indicative of the
presence of a reduced disease awareness.
Statistical analysis
Statistical analyses were carried out using the Statistical
Package for Social Science (SPSS), version 21.0 and were
performed by a medical statistician.
Demographic and clinical variables were compared be-
tween groups using the Pearson chi-square for categor-
ical variables, Student t test and the Mann–Whitney U
test. Cognitive scores were converted as means (and
ranges) or frequencies (and percentages) of subjects with
pathological scores.
The p value < 0.05 was considered statistically sig-
nificant. All statistical tests were two tailed.
In order to investigate the relationship between clinical
data and psychological variables, we computed the bi-
variate correlation coefficients, Pearson’s coefficient for
parametric variables and Spearman’s coefficient for non
parametric variables. An exploratory forward stepwise
logistic regression analysis was carried out to deter-
mine which cognitive domains are best related to
DM1 brain dysfunction; group (patients vs controls)
was the dependent variable and TMT-A, TMT-B,
WCST, STROOP, ROCF-copy, ROCF-IR, ROCF-DR
and CBT as predictor variables, in order to detect the
most affecting cognitive tests in DM1 patients. We
performed Bland-Altman plot with 95 % limits of
agreements for the combined graphical/statistical in-
terpretation of patients’ self evaluation of muscular
weakness (INQoL Weakness Domain score) to clini-
cian’s objective muscular evaluation (MIRS).
Results
Neurological assessment
All patients were molecularly defined and grouped on
the basis of CTG expansion size as follows: E1 (<150
CTG; 33.7 %), E2 (150–1000 CTG; 58.5 %), E3 (>1000
CTG; 3.8 %) (Table 1). MIRS scores varied between 1 to
5 (mild to severe impairment), with a prevalence of
mild/moderate involvement (7.3 % of patients with
MIRS 1; 36.4 % with MIRS 2; 27.3 % with MIRS 3;
21.8 % with MIRS 4; 7.3 % scored MIRS 5; MIRS mean
value 2.85 ± 1) (Table 1). Mean time from disease onset
was 10.2 ± 7.4 years. Patients’ mean educational level
was level was 11.6 ± 3.5 years.
Neuropsychological assessment
Overall, DM1 patients did not show severe depressive or
anxiety symptoms as assessed respectively by BDI-II and
STAI-Y2, while in these subjects there is a tendency to
observe mixed mood conditions together with apathetic
behaviour (Table 2). Patients obtained lower scores than
matched controls in most neuropsychological tests
(Table 3). Notably, in patients we found that several cog-
nitive performances resulted impaired (Fig. 1). Cognitive
profile appeared heterogeneous, with no significant dif-
ferences in cognitive performance between female and
male patients. Main impairments were found in execu-
tive (Stroop, WCST) and mnesic domains with visuo-
spatial involvement (ROCF-copy and DR, CBT). Interest-
ingly, verbal memory abilities (RAVLT, Digit span) were
rather preserved, suggesting a dissociation between ver-
bal and spatial abilities.
Executive functioning was assessed using the specific
cognitive tests previously described in Methods section.
TMT A was impaired in 21.3 % of patients, TMT B in
17.4 %, FAB in 25 % and FAS in 25.5 %.
Impairments in Stroop test (Error Interference 32.7 %,
Time Interference 36.7 %) and WCST (Categories
43.4 %, Perseverative Errors 47.2 %) were more fre-
quently detected, pointing out the patients’ significant
difficulties in engaging attentional resources to inhibit
automatic behavioural responses, in using environmental
feedback to shift cognitive sets, in directing behaviour
toward the achievement of a goal, and in modulating
perseverative responding. The high incidence of persev-
erations assessed in our sample suggest an inefficient
initial conceptualization with consequent learning dys-
function across stages.
Immediate memory was tested with CBT for spatial
performance and with Digit Span for verbal perform-
ance; 43.1 % of patients showed CBT impairment, while
24 % had impairment in Digit Span. As for delayed recall
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memory, only 1.9 % showed RVLT-DR impaired perfor-
mances, while 36.7 % had impaired ROCF-DR.
Motor planning and visuo-spatial abilities, tested using
ROCF, widely ranked below the normal range, with
46.9 % of patients with impaired performance. However,
perceptual skills, assessed both by clinical and neuro-
psychological examination, were normal (Table 3, Fig. 1).
There was a decrease in cognitive performance
related to age in the majority of the cognitive domains
examined [RAVLT IR (r =−.348, p = .011) and DR (r =
−.426, p = .002), CBT (r = −.423, p = .002), TMT A (r
= .475, p = .001), TMT B (r = .559, p < .001),ROCF (r
= −.445, p = .001), FAB (r = −.507, p < .001), Stroop
time interference (r = .348, p = 0.14), PM47 (r = −.403,
p = .003), WCST perseverative errors (r = .434, p = .001)],
although data of follow up are not available in order
to establish the degree of DM1-correlated cognitive im-
pairment progression by aging.
It is important to note that the results of some cogni-
tive tests could be impaired by the concomitant motor
disability due to the muscle disease influencing test pro-
cedure’s and performance skills. For instance, within the
men group the motor planning performance (FAB test,
item number 3 consisting in Lurjia motor series) was af-
fected by the presence of hand muscular strength im-
pairment and myotonia, scored by MIRS (Spearman r =
−.409, p = .025). Instead, among women, MIRS nega-
tively correlated with visuo-constructive and spatial
memory function, tested by ROCF-copy and IR (Spear-
man r1 = −.522, p = .046, r2 = −.583, p = .023).
The regression analysis was performed considering
the most impaired test (TMT-A, TMT-B, WCST,
STROOP, ROCF, CBT) as predictive variables and two
test entered the model, ROCF-copy and CBT
(Table 4). The model correctly predicted patients vs
controls in 76.7 % of cases.
Moreover group comparison analysis showed that ano-
sognosic patients had a higher impairment (p < 0.05) in
visuo-spatial memory functioning (CBT), cognitive flexi-
bility and conceptualization (WCST Cat, Ep) (Table 5).
Abstract reasoning, measured by using the Coloured
Raven Progressive Matrices (PM47) was altered only in a
small percentage of patients (18.9 %). Severe attention
deficits were not detected.
Evaluation of quality of life
Figure 2 and Table 6 show the altered domains of quality
of life detected by INQoL interview in DM1 patients.
According to previous observations [38, 39], also in
our analysis the INQoL Total score (19.1) revealed a
mild impact of disease disability on quality of life in
DM1 patients, probably related to the difficulties in cog-
nition and the lack of interest. By considering the single
INQoL Domain Scores, we observed that the Weakness
domain had the worst impact (49.3), as well as the Fa-
tigue domain (44.6). Nevertheless, Body Image and So-
cial relationships domains (respectively 5.6 and 13)
seemed to be less affected by the disabling effects of dis-
ease. Female patients were more likely to refer depressed
mood (item 8) than males; no other gender difference
were found in INQoL domains analysis (Fig. 2).
Assessment of disease unawareness
The majority of patients were roughly able to describe
their behaviours when they were tested by INQoL, al-
though they could not show consistent emotional
Fig. 1 Percentages of DM1 patients who show critically relevant neuropsychological dysfunctions across different cognitive domains (N = 65).
Percentages of impairment (%) are related to available cut-off scores of normality (≥95 % of the tolerance limit of the normal
population distribution)
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concern about the consequences of their physical and
behavioural symptoms (Fig. 3, Table 6).
Overall, by comparing patients’ self evaluation of
muscular weakness (INQoL Weakness Domain score)
to clinician’s objective muscular evaluation (MIRS),
we found a significant direct correlation between
these two measures (r = 0.50; p < 0.05). However, by
using Bland-Altman plot analysis (Fig. 4), we ob-
served a good agreement between patients’ INQoL
Weakness score and MIRS only for subjects with a
more severe motor impairment (mean of MIRS and
INQoL weakness ≥3, Fig. 4). A reduced agreement
was instead detected for subjects with a milder mus-
cular phenotype (18.7 %), thus indicating the pres-
ence of motor impairment understatement in this
subgroup of patients.
Caregivers were predominantly women (63 %, n = 41),
ranging from 28 to 70 years of age; they were primarily
spouses (56.9 %, n = 37) or parents (32.3 %, n = 21) living
at home with the patients.
Internal discrepancies between DM1 patient INQoL
self-ratings and main caregiver’s reports were detected
in 51.6 % of cases. We observed that patients tended to
understate some aspects of their psycho-social difficul-
ties. Notably, statistical analysis revealed a reduced
awareness of disease that raised when patients were
asked to talk about Life Domains of INQoL, especially
Independence (52.4 %) and Social Relationships (47.6 %),
(Fig. 3, Table 6) thus suggesting an impairment in self-
appraisal of their adaptive behaviours and interaction
with the environment.
Notably, normal awareness was detected in INQoL do-
mains concerning the emotional sphere and, overall, a
mild occurrence of unawareness was observed about
mood alterations (anxiety 19.4 %, depression 16.1 %). No
group differences between anosognosic and non anosog-
nosic patients were detected in mood assessment scales
(BDI-II p = 0.969, STAI-Y2 p = 0.787, AES p = 0.386).
Discussion
Although CNS impairment and reduced compliance are
well documented, to our knowledge this is the first at-
tempt to investigate disturbances in awareness in DM1
patients, in association with neuropsychological profile
and other clinical and demographic variables. Overall,
Table 4 Stepwise logistic regression analysis in 81 subjects (65
DM1 patients, 26 healthy subjects): CBT and ROCF-copy perfor-
mances as predicting variables
STEP Cognitive test b (SE) O.R. C.I. 95 % P
1 Constant 6.56 (1.78) - - -
CBT −1.31 (0.38) 0.27 0.13–0.57 .001
2 Constant 8.19 (2.07) - - -
CBT −1.21 (0.41) 0.30 0.13–0.67 .003
ROCF-copy −1.13 (0.05) 0.88 0.80–0.97 .007
STEP 2 R2 : Cox-Snell = .29, Nagelkerke = .40, Hosmer-Lemenshow:
chi-square = 7.36, p = .498
percentage of overall correct prediction = 76.7 %
Table 5 Group comparison between anosognosic (n = 33) and non anosognosic (n = 31) DM1 patients, in cognitive domains of
functioning; statistically significant p-values are shown in bold
Anosognosic (n = 33) Non anosognosic (n = 31)
mean corrected scores (SD) mean corrected scores (SD) p-value
RAVLT IR 41.1 (7.8) 42.1 (6.9) .612
RAVLT DR 9.0 (1.7) 9.1 (1.8) .851
Rey Osterrieth Figure (ROCF) Copy 27.6 (6.1) 28.5 (5.7) .597
Rey Osterrieth Figure (ROCF) IR 12.8 (6.3) 15.5 (5.5) .124
Rey Osterrieth Figure (ROCF) DR 12.3 (6.6) 14.5 (6.8) .265
Digit Span 5.1 (1.2) 5.2 (1.1) .813
Corsi’s Block Test (CBT) 3.9 (0.8) 4.4 (0.6) .060a
Trail Making Test A (TMT A) 54.1 (19.9) 57.8 (46.1) .732
Trail making Test B (TMT B) 140.2 (78.9) 122.3 (31.4) .351
FAS (phonemic fluency) 26.3 (8.7) 31.3 (10.5) .083
FAB 15.1 (1.2) 15.3 (1.4) .576
STROOP Time Interference 33.5 (28.4) 32.4 (22.2) .881
STROOP Error Interference 3.4 (5.3) 2.5 (2.6) .487
PM47 25.5 (0.3) 27.5 (4.2) .202
WCST Categories (Cat) 3.0 (1.9) 4.7 (1.5) .001
WCST Perseverative Errors (pe) 6.7 (4.6) 4.0 (3.4) .028
a considerable trend toward significance
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our evidences, rather than a general disease unaware-
ness, support far more unawareness for particular psy-
chosocial and behavioural aspects in DM1 patients.
Since psychological tools for anosognosia evaluation
have to be disease-specific, here we proposed a novel
neuropsychological protocol to investigate disease un-
awareness in DM1 patients by analysing the discrepancy
of the INQoL scores between patient and caregiver’s re-
port [35]. INQoL interview allowed us to detect
symptom-specific issues in neuromuscular disorders,
usually disregarded by common questionnaires, through
the investigation of patient perception. The discrepancy
of the INQoL scores was taken into account separately
in each domain of every-day-life functioning in order to
achieve a characterization of awareness at a single-
domain specificity level. Data elaboration revealed that a
high percentage (51.6 %) of DM1 patients was unaware
of symptoms across different physical and life domains
investigated by INQoL interview. In particular, the ano-
sognosia was mostly associated to domains of Independ-
ence and Relationships. Despite clear limitations in
social functioning, such as work inability or progressive
withdrawal from relationships, patients appeared uncon-
cerned about that, as confirmed by caregivers’ reports.
Nevertheless, these data could also reflect the effects of
patient’s unawareness on the relationship with the main
caregiver in coping with illness-related problems.
Interestingly emotional dimensions did not substan-
tially take part to disease unawareness in our sample also
for the difficulty, inherent to the nature itself of the ad-
ministered questions to plenty capture, for both patients
and caregivers, emotional reactions to the disease.
From a neuropsychological point of view, most of our
patients presented main cognitive impairment in execu-
tive and mnesic domains with visuo-spatial involvement,
coherently with literature [10, 16, 17]. Patients’
Fig. 2 INQoL Domain Scores representing the impact of each impaired domain on patients quality of life; the bars show standard errors. Higher
scores indicate the higher impact of disease (N = 64)
Table 6 Characteristics of patients’ and caregiver’s reports at INQoL interview; discrepancy scores are shown in bold (N = 64)







score – patient score)
N° pt. with reduced
awareness of illness (%)
1. Weakness (0–19) - 10.1 (5.4) - -
2. Stiffening (0–19) - 7.4 (6) - -
3. Pain (0–19) - 5.1 (6) - -
4. Fatigue (0–19) - 8.9 (5.6) - -
5. Activity (0–18) - 11.1 (8.3) 10.9 (10.6) 0.2 23 (35.9)
6. Independence (0–18) - 6.2 (5.4) 7.9 (5.6) 1.7* 24 (37.5)
7. Relationships (0–24) - 6.8 (8.7) 10.1 (11.8) 3.3* 27 (42.2)
8. Emotional Anxiety (0–6) 2.3 (1.7) 2.8 (1.9) 0.5 7 (10.9)
Depression (0–
6)
1.8 (1.7) 1.8 (1.7) 0.0 6 (9.3)
Frustration (0–
6)
1.3 (1.7) 1.8 (1.8) 0.5 8 (12.5)
Self-esteem
(0–6)
1.1 (1.6) 1.6 (1.7) 0.5 7 (10.4)
9. Physical appearance
(0–18)
- 5.6 (4.6) - - -
INQoL total mean (SD) = 19.1 (13.1)
* Statistical significance at p < 0.05
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performance suggested that in this sample disease un-
awareness was related to cognitive dysfunction, specific-
ally with lower scores in visuo-spatial memory, cognitive
flexibility, comprehension and conceptualization. Fur-
thermore the neuropsychological tests exploring these
cognitive domains, such as CBT and ROCF-copy,
showed good sensitivity in discriminating DM1 patients
performance vs healthy controls in 76.7 % of cases. We
believe that “cognitive indicators” could be useful for fu-
ture research aimed at defining reliable outcome mea-
sures of DM1 neuropsychological involvement and
progression.
Some possible methodological limitations of our study,
such as sample size discrepancy between patients and
controls, or lacking of data on possible impact of family
burden on the caregiver, have to be addressed for future
studies.
Nonetheless and with the above considerations, ano-
sognosia with a structured profile remains a recurrent
feature in DM1, significantly associated to cognitive im-
pairment. Our observations are in line with some theor-
etical models, such as the Cognitive Awareness Model
[40] and Petrified Self Model [41] that identify self-
awareness as a metacognitive function relying on high-
Fig. 3 Patients (blue) vs main caregiver (red) mean ratings in INQoL Life Domains (N = 64)
Fig. 4 Bland-Altman plot with 95 % limits of agreements for the combined graphical/statistical interpretation of patients’ self evaluation of
muscular weakness (INQoL Weakness Domain score) to clinician’s objective muscular evaluation (MIRS) in DM1 patients. The differences between
MIRS and INQoL Weakness Domain score are plotted against their mean and the mean difference; light spots indicate single observation, dark
spots indicate collinear observations; 95 % confidence limit lines are drawn (brown dotted lines)
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order cognitive abilities with consistent structural and
functional connectivity with frontal circuitry. More-
over these results are coherent with the hypothesis
that DM1 patients present dysfunctions in social cog-
nition, that is a set of psychological processes includ-
ing recognizing common social knowledge and
emotional relevance of everyday information coming
from the environment [21, 26].
Based on literature evidences, we can hypothesize
that anosognosia in DM1 patients is related to brain
dysfunction [42]. Several recent neuroimaging studies
have implicated various aspects of self-awareness with
the frontal lobes and parietal structures [43]. Func-
tional MRI studies have repeatedly observed two large
and closely interconnected neural networks, the de-
fault mode network (DMN) and the “attention sys-
tem”, involving respectively medial prefrontal cortex
(mPFC), posterior cingulated cortex (pCC), inferior
parietal lobule (IPL), lateral and inferior temporal cor-
tex, medial temporal lobe, and dorso-lateral prefrontal
cortex (dlPFC), dorsal anterior cingulated cortex,
frontal eye fields and extrastriate cortex [44].
Thus it will be suitable to warrant further research to
elucidate the mechanisms of anosognosia. Our team is
still working on neuroanatomical correlates and func-
tional connectivity of anosognosia by advanced MRI
techniques (data not published).
Conclusions
Finally, gaining a better understanding of anosognosia
could improve prognostication, enable timely interven-
tions for DM1 patients, and assist caregivers in early
care planning. A cognitive-behavioural and physical ex-
ercise intervention trial could be part of the therapeutic
strategies aimed to improve quality of life [45]. This is
mandatory to prevent detrimental events related to dis-
ease progression and to attain specific clinical protocols
in preparation of trial readiness.
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